【大行评级|招银国际:上调巨子生物目标价至79.96港元 去年业绩表现强劲】招银国际发表研究报告指,巨子生物去年业绩表现强劲,其中收入按年升57%至55亿元。该行相信,巨子生物产品组合成功扩展有助推动其长期快速增长,另外,四种注射产品目前正处于申请阶段,并即将商业化。该行将其目标价由69.19港元上调至79.96港元,维持“买入”评级。

金融界
03 Apr
招银国际发表研究报告指,巨子生物去年业绩表现强劲,其中收入按年升57%至55亿元。该行相信,巨子生物产品组合成功扩展有助推动其长期快速增长,另外,四种注射产品目前正处于申请阶段,并即将商业化。该行将其目标价由69.19港元上调至79.96港元,维持“买入”评级。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10